U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07300644) titled 'Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years' on Nov. 24.
Brief Summary: A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.
The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.
Study Start Date: Nov. 25
Study Type: INTERVENTIONAL
Condition:
Pneumococcal Infectious Disease
Intervention:
BIOLOGICAL: Sinovac PCV24
Sinovac PC...